Search

everythinglearnresearchcommunity

for

Search:↓

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Hair loss can be caused by stress, infections, drugs, and various diseases, with treatment depending on accurate diagnosis.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

A patient grew extra hair on their ears after treatment for testicular cancer, possibly due to hormonal changes or genetics.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Agaricus bisporus derived β-Glucan could be an effective cervical cancer treatment with antimicrobial and antioxidant properties.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

Understanding phenotypic plasticity is crucial for developing effective cancer therapies.

Opioid painkillers can cause many side effects, including breathing problems and addiction, but are generally considered safe when used properly.

PLD is an effective and safer alternative for treating breast cancer.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Different factors affect where drugs are absorbed in the small intestine, which is important for effective medication use.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.